Ceria Therapeutics, Inc. Awarded a $300,000 SBIR Grant to Advance Development of a Novel Treatment of Non-Healing Diabetic Foot Ulcers

Ceria Therapeutics, Inc. (Ceria), a Colorado-based biotech startup
focusing on the development of novel therapeutics to address several inflammatory diseases, today announced the company has received a second Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). This award is directed to development of CTX-001 for the treatment of non-healing diabetic foot ulcers (DFUs).